NPS pockets $30M, parts ways with AstraZeneca

NPS Pharmaceuticals and AstraZeneca are ending their six-year-old collaboration to develop new drugs for metabotropic glutamate receptors, or mGluRs. AstraZeneca is paying NPS $30 million for the full rights to the research. NPS says it will earmark these new funds for late-stage product development.

"This strategic move creates investment flexibility for NPS and enables us to use the monies from this deal, the previously announced Nycomed GATTEX deal and the approximately $10 million in savings over the next two years from this transaction to support the further development of our late-stage pipeline products, PREOS and GATTEX, in specialty indications," said NPS CEO Tony Coles.

- see the release on the breakup 

ALSO: Just yesterday billionaire George Soros cut his investment in NPS to 1.8 percent. Report

Related Articles:
Analyst puts NPS Pharma under microscope. Report
NPS sells drug rights. Report
NPS halves workforce in restructuring. Report
NPS sells two facilities. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.